Corona Remedies IPO Allotment LIVE: Strong GMP Points to 28% Listing Gain — Check Your Allotment Status Online
Today is the day for the Corona Remedies IPO allotment to be released followed by a strong GMP which signifies an increase of up to 28% in listing gains. Get the entire allotment guide along with the subscription details, GMP trends, company financials, key risks, and the method to check your allotment status at NSE, BSE, and Bigshare Services.
image for illustrative purpose
The IPO of Coron Remedies has been one of the most awaited allotments and it is now live. The overwhelming response with which the pharmaceutical company's IPO was closed cases of investment; checking allotment status has become of prime importance. The company has announced that the official allotment date is December 11.
The public offer of ₹655.37 crores received phenomenal demand with final subscription being 137.04 times. As per the data of NSE, the bids were placed by investors for 62.65 crore shares against the availability of 45.71 lakh shares.
The breakdown reflects immense excitement:
QIBs: 278.52 times
NIIs: 208.88 times
Retail Investors (RIIs): 28.73 times
IPO Structure & Company Overview
The issue was entirely an Offer for Sale (OFS) from the promoters and existing shareholders including Sepia Investments, Anchor Partners, and Sage Investment Trust. Corona Remedies having its headquarters in Ahmedabad focuses on pharmaceutical formulations across the segments of women's health, cardio-diabetes, pain management, urology, and others. The company had a strong portfolio of 67 brands in December 2024.
GMP Predicts Significant Increase in Listing Price
The grey market premium (GMP) continues to be impressive. If the GMP is set at ₹295, then the estimated listing price is around ₹1,357, which is a 27.78% gain over the issue price of ₹1,062.
How to Check Corona Remedies IPO Allotment Status
Your allotment status can be verified on three platforms — NSE, BSE, and Bigshare Services (the registrar).
NSE
Go to the NSE IPO bid check page.
Select the Equity & SME IPO option.
Get Corona Remedies.
Provide your PAN and application number.
Click on Submit.
BSE
Open BSE’s allotment status page.
Pick the Equity option.
Click on Corona Remedies Ltd.
Input PAN or application number.
Then click on verify and search.
Bigshare Services
Go to Bigshareonline.com.
Click on Corona Remedies Ltd.
Provide application no./beneficiary ID/PAN.
Complete captcha and carry out the search.
Key Company Highlights & Growth Drivers
One among India’s top 30 pharma companies and lessening the growth periods remarkably.
Chronic and sub-chronic disease areas are the segments with the strongest sales and they contribute over 70% of the revenue.
The 27 leading “engine brands” that include Cor, Trazer, COR9, B-29, and Myoril, are responsible for the 72% sales.
More global partners coming in, for example, Ferring Pharmaceuticals is among them.
The company's distribution network is very strong, as it has 22 C&F agents, more than 2000 distributors, and 2671 medical representatives within India.
The company has two manufacturing facilities and two R&D centers recognized by DSIR as well.
For FY25 revenue of ₹1,196.4 crore, which is a 17.9% rise YoY.
The same period witnessed a 65.1% year-on-year increase in PAT to ₹149.4 crore.
Industry Outlook
At present, India’s domestic pharmaceutical market is ₹2.3 trillion worth, by FY2030 it is expected to reach ₹3.3–3.5 trillion valuation, primarily on account of increased prevalence of chronic diseases and wider availability of quality healthcare.
Risks to Watch
Dependency on a few therapy areas and engine brands is very high.
Almost entirely reliance on the domestic market for revenue (96%+).
Short-term supply contracts with third-party raw material suppliers, this dependency being high.
The listing of Corona Remedies IPO is expected to yield substantial profits for those investors who were lucky enough to get the allotment as the pharmaceutical sector has been on a strong growth trajectory.
